Weill Cornell Medicine has received complementary grants from Genentech and the Leukemia & Lymphoma Society (LLS) to support a new program that aims to address socioeconomic and racial disparities and increase access to clinical trials for underserved patients with blood cancers living in Brooklyn and Queens.
The environment surrounding the cancerous cells of a lymphoma tumor has a strong influence on the progression of these blood-cell cancers and their responses to therapies.
Weill Cornell Medicine neuroscientist Dr. Li Gan is driving toward one of the most coveted medical breakthroughs: an effective treatment for Alzheimer’s disease.
Dr. John Leonard, an esteemed physician-scientist who specializes in lymphoma research and treatment, has been named senior associate dean for innovation and initiatives at Weill Cornell Medicine.
The addition of an oral immunomodulatory drug to a commonly employed antibody therapy is more effective against chronic, indolent lymphoma than the antibody alone, according to the results of a Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant (P01) from the National Cancer Institute (NCI) to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time.
Newer, non-chemotherapy drugs benefit many patients with mantle cell lymphoma, an incurable form of blood cancer, and deserve deeper study in clinical trials, according to an editorial published Sept. 12 in Blood by scientists at Weill Cornell Medicine and NewYork-Presbyterian.
Dr. Robert Burakoff has been named vice chair for ambulatory services for the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, and site chief for the Division of Gastroenterology and Hepatology at NewYork-Presbyterian Lower Manhattan Hospital and Weill Cornell Medicine.
